The global market for Anti-VEGF Medicine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Anti-VEGF Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Anti-VEGF Medicine players cover Faricimab, Bayer (Regeneron), Brolucizumab, Kanghong Pharmaceutical and Santen. etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Anti-VEGF Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Anti-VEGF Medicine market, with both quantitative and qualitative data, to help readers understand how the Anti-VEGF Medicine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Anti-VEGF Medicine market and forecasts the market size by Type (Single Target (Ranibizumab, etc.) and Multiple Targets (Aflibercept, Conbercept, etc.),), by Application (Hospital, Eye Clinic and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Single Target (Ranibizumab, etc.)
Multiple Targets (Aflibercept, Conbercept, etc.)
Segmentation by application
Hospital
Eye Clinic
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Faricimab
Bayer (Regeneron)
Brolucizumab
Kanghong Pharmaceutical
Santen
Chapter Introduction
Chapter 1: Scope of Anti-VEGF Medicine, Research Methodology, etc.
Chapter 2: Executive Summary, global Anti-VEGF Medicine market size (sales and revenue) and CAGR, Anti-VEGF Medicine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Anti-VEGF Medicine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Anti-VEGF Medicine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Anti-VEGF Medicine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Faricimab, Bayer (Regeneron), Brolucizumab, Kanghong Pharmaceutical and Santen, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anti-VEGF Medicine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Anti-VEGF Medicine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Anti-VEGF Medicine by Country/Region, 2017, 2022 & 2028
2.2 Anti-VEGF Medicine Segment by Type
2.2.1 Single Target (Ranibizumab, etc.)
2.2.2 Multiple Targets (Aflibercept, Conbercept, etc.)
2.3 Anti-VEGF Medicine Sales by Type
2.3.1 Global Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
2.3.2 Global Anti-VEGF Medicine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Anti-VEGF Medicine Sale Price by Type (2017-2022)
2.4 Anti-VEGF Medicine Segment by Application
2.4.1 Hospital
2.4.2 Eye Clinic
2.4.3 Other
2.5 Anti-VEGF Medicine Sales by Application
2.5.1 Global Anti-VEGF Medicine Sale Market Share by Application (2017-2022)
2.5.2 Global Anti-VEGF Medicine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Anti-VEGF Medicine Sale Price by Application (2017-2022)
3 Global Anti-VEGF Medicine by Company
3.1 Global Anti-VEGF Medicine Breakdown Data by Company
3.1.1 Global Anti-VEGF Medicine Annual Sales by Company (2020-2022)
3.1.2 Global Anti-VEGF Medicine Sales Market Share by Company (2020-2022)
3.2 Global Anti-VEGF Medicine Annual Revenue by Company (2020-2022)
3.2.1 Global Anti-VEGF Medicine Revenue by Company (2020-2022)
3.2.2 Global Anti-VEGF Medicine Revenue Market Share by Company (2020-2022)
3.3 Global Anti-VEGF Medicine Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Medicine Product Location Distribution
3.4.2 Players Anti-VEGF Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Anti-VEGF Medicine by Geographic Region
4.1 World Historic Anti-VEGF Medicine Market Size by Geographic Region (2017-2022)
4.1.1 Global Anti-VEGF Medicine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Anti-VEGF Medicine Annual Revenue by Geographic Region
4.2 World Historic Anti-VEGF Medicine Market Size by Country/Region (2017-2022)
4.2.1 Global Anti-VEGF Medicine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Anti-VEGF Medicine Annual Revenue by Country/Region
4.3 Americas Anti-VEGF Medicine Sales Growth
4.4 APAC Anti-VEGF Medicine Sales Growth
4.5 Europe Anti-VEGF Medicine Sales Growth
4.6 Middle East & Africa Anti-VEGF Medicine Sales Growth
5 Americas
5.1 Americas Anti-VEGF Medicine Sales by Country
5.1.1 Americas Anti-VEGF Medicine Sales by Country (2017-2022)
5.1.2 Americas Anti-VEGF Medicine Revenue by Country (2017-2022)
5.2 Americas Anti-VEGF Medicine Sales by Type
5.3 Americas Anti-VEGF Medicine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Medicine Sales by Region
6.1.1 APAC Anti-VEGF Medicine Sales by Region (2017-2022)
6.1.2 APAC Anti-VEGF Medicine Revenue by Region (2017-2022)
6.2 APAC Anti-VEGF Medicine Sales by Type
6.3 APAC Anti-VEGF Medicine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Anti-VEGF Medicine by Country
7.1.1 Europe Anti-VEGF Medicine Sales by Country (2017-2022)
7.1.2 Europe Anti-VEGF Medicine Revenue by Country (2017-2022)
7.2 Europe Anti-VEGF Medicine Sales by Type
7.3 Europe Anti-VEGF Medicine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Anti-VEGF Medicine by Country
8.1.1 Middle East & Africa Anti-VEGF Medicine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Anti-VEGF Medicine Revenue by Country (2017-2022)
8.2 Middle East & Africa Anti-VEGF Medicine Sales by Type
8.3 Middle East & Africa Anti-VEGF Medicine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Medicine
10.3 Manufacturing Process Analysis of Anti-VEGF Medicine
10.4 Industry Chain Structure of Anti-VEGF Medicine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Medicine Distributors
11.3 Anti-VEGF Medicine Customer
12 World Forecast Review for Anti-VEGF Medicine by Geographic Region
12.1 Global Anti-VEGF Medicine Market Size Forecast by Region
12.1.1 Global Anti-VEGF Medicine Forecast by Region (2023-2028)
12.1.2 Global Anti-VEGF Medicine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-VEGF Medicine Forecast by Type
12.7 Global Anti-VEGF Medicine Forecast by Application
13 Key Players Analysis
13.1 Faricimab
13.1.1 Faricimab Company Information
13.1.2 Faricimab Anti-VEGF Medicine Product Offered
13.1.3 Faricimab Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Faricimab Main Business Overview
13.1.5 Faricimab Latest Developments
13.2 Bayer (Regeneron)
13.2.1 Bayer (Regeneron) Company Information
13.2.2 Bayer (Regeneron) Anti-VEGF Medicine Product Offered
13.2.3 Bayer (Regeneron) Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bayer (Regeneron) Main Business Overview
13.2.5 Bayer (Regeneron) Latest Developments
13.3 Brolucizumab
13.3.1 Brolucizumab Company Information
13.3.2 Brolucizumab Anti-VEGF Medicine Product Offered
13.3.3 Brolucizumab Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Brolucizumab Main Business Overview
13.3.5 Brolucizumab Latest Developments
13.4 Kanghong Pharmaceutical
13.4.1 Kanghong Pharmaceutical Company Information
13.4.2 Kanghong Pharmaceutical Anti-VEGF Medicine Product Offered
13.4.3 Kanghong Pharmaceutical Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Kanghong Pharmaceutical Main Business Overview
13.4.5 Kanghong Pharmaceutical Latest Developments
13.5 Santen
13.5.1 Santen Company Information
13.5.2 Santen Anti-VEGF Medicine Product Offered
13.5.3 Santen Anti-VEGF Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Santen Main Business Overview
13.5.5 Santen Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Anti-VEGF Medicine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Anti-VEGF Medicine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Single Target (Ranibizumab, etc.)
Table 4. Major Players of Multiple Targets (Aflibercept, Conbercept, etc.)
Table 5. Global Anti-VEGF Medicine Sales by Type (2017-2022) & (K Units)
Table 6. Global Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
Table 7. Global Anti-VEGF Medicine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Anti-VEGF Medicine Revenue Market Share by Type (2017-2022)
Table 9. Global Anti-VEGF Medicine Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Anti-VEGF Medicine Sales by Application (2017-2022) & (K Units)
Table 11. Global Anti-VEGF Medicine Sales Market Share by Application (2017-2022)
Table 12. Global Anti-VEGF Medicine Revenue by Application (2017-2022)
Table 13. Global Anti-VEGF Medicine Revenue Market Share by Application (2017-2022)
Table 14. Global Anti-VEGF Medicine Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Anti-VEGF Medicine Sales by Company (2020-2022) & (K Units)
Table 16. Global Anti-VEGF Medicine Sales Market Share by Company (2020-2022)
Table 17. Global Anti-VEGF Medicine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Anti-VEGF Medicine Revenue Market Share by Company (2020-2022)
Table 19. Global Anti-VEGF Medicine Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Anti-VEGF Medicine Producing Area Distribution and Sales Area
Table 21. Players Anti-VEGF Medicine Products Offered
Table 22. Anti-VEGF Medicine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Anti-VEGF Medicine Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Anti-VEGF Medicine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Anti-VEGF Medicine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Anti-VEGF Medicine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Anti-VEGF Medicine Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Anti-VEGF Medicine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Anti-VEGF Medicine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Anti-VEGF Medicine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Anti-VEGF Medicine Sales by Country (2017-2022) & (K Units)
Table 34. Americas Anti-VEGF Medicine Sales Market Share by Country (2017-2022)
Table 35. Americas Anti-VEGF Medicine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Anti-VEGF Medicine Revenue Market Share by Country (2017-2022)
Table 37. Americas Anti-VEGF Medicine Sales by Type (2017-2022) & (K Units)
Table 38. Americas Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
Table 39. Americas Anti-VEGF Medicine Sales by Application (2017-2022) & (K Units)
Table 40. Americas Anti-VEGF Medicine Sales Market Share by Application (2017-2022)
Table 41. APAC Anti-VEGF Medicine Sales by Region (2017-2022) & (K Units)
Table 42. APAC Anti-VEGF Medicine Sales Market Share by Region (2017-2022)
Table 43. APAC Anti-VEGF Medicine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Anti-VEGF Medicine Revenue Market Share by Region (2017-2022)
Table 45. APAC Anti-VEGF Medicine Sales by Type (2017-2022) & (K Units)
Table 46. APAC Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
Table 47. APAC Anti-VEGF Medicine Sales by Application (2017-2022) & (K Units)
Table 48. APAC Anti-VEGF Medicine Sales Market Share by Application (2017-2022)
Table 49. Europe Anti-VEGF Medicine Sales by Country (2017-2022) & (K Units)
Table 50. Europe Anti-VEGF Medicine Sales Market Share by Country (2017-2022)
Table 51. Europe Anti-VEGF Medicine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Anti-VEGF Medicine Revenue Market Share by Country (2017-2022)
Table 53. Europe Anti-VEGF Medicine Sales by Type (2017-2022) & (K Units)
Table 54. Europe Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
Table 55. Europe Anti-VEGF Medicine Sales by Application (2017-2022) & (K Units)
Table 56. Europe Anti-VEGF Medicine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Anti-VEGF Medicine Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Anti-VEGF Medicine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Anti-VEGF Medicine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Anti-VEGF Medicine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Anti-VEGF Medicine Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Anti-VEGF Medicine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Anti-VEGF Medicine Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Anti-VEGF Medicine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Anti-VEGF Medicine
Table 66. Key Market Challenges & Risks of Anti-VEGF Medicine
Table 67. Key Industry Trends of Anti-VEGF Medicine
Table 68. Anti-VEGF Medicine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Anti-VEGF Medicine Distributors List
Table 71. Anti-VEGF Medicine Customer List
Table 72. Global Anti-VEGF Medicine Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Anti-VEGF Medicine Sales Market Forecast by Region
Table 74. Global Anti-VEGF Medicine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Anti-VEGF Medicine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Anti-VEGF Medicine Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Anti-VEGF Medicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Anti-VEGF Medicine Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Anti-VEGF Medicine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Anti-VEGF Medicine Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Anti-VEGF Medicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Anti-VEGF Medicine Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Anti-VEGF Medicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Anti-VEGF Medicine Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Anti-VEGF Medicine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Anti-VEGF Medicine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Anti-VEGF Medicine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Anti-VEGF Medicine Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Anti-VEGF Medicine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Anti-VEGF Medicine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Anti-VEGF Medicine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Faricimab Basic Information, Anti-VEGF Medicine Manufacturing Base, Sales Area and Its Competitors
Table 93. Faricimab Anti-VEGF Medicine Product Offered
Table 94. Faricimab Anti-VEGF Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Faricimab Main Business
Table 96. Faricimab Latest Developments
Table 97. Bayer (Regeneron) Basic Information, Anti-VEGF Medicine Manufacturing Base, Sales Area and Its Competitors
Table 98. Bayer (Regeneron) Anti-VEGF Medicine Product Offered
Table 99. Bayer (Regeneron) Anti-VEGF Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Bayer (Regeneron) Main Business
Table 101. Bayer (Regeneron) Latest Developments
Table 102. Brolucizumab Basic Information, Anti-VEGF Medicine Manufacturing Base, Sales Area and Its Competitors
Table 103. Brolucizumab Anti-VEGF Medicine Product Offered
Table 104. Brolucizumab Anti-VEGF Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Brolucizumab Main Business
Table 106. Brolucizumab Latest Developments
Table 107. Kanghong Pharmaceutical Basic Information, Anti-VEGF Medicine Manufacturing Base, Sales Area and Its Competitors
Table 108. Kanghong Pharmaceutical Anti-VEGF Medicine Product Offered
Table 109. Kanghong Pharmaceutical Anti-VEGF Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Kanghong Pharmaceutical Main Business
Table 111. Kanghong Pharmaceutical Latest Developments
Table 112. Santen Basic Information, Anti-VEGF Medicine Manufacturing Base, Sales Area and Its Competitors
Table 113. Santen Anti-VEGF Medicine Product Offered
Table 114. Santen Anti-VEGF Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Santen Main Business
Table 116. Santen Latest Developments
List of Figures
Figure 1. Picture of Anti-VEGF Medicine
Figure 2. Anti-VEGF Medicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Medicine Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Anti-VEGF Medicine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Anti-VEGF Medicine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Single Target (Ranibizumab, etc.)
Figure 10. Product Picture of Multiple Targets (Aflibercept, Conbercept, etc.)
Figure 11. Global Anti-VEGF Medicine Sales Market Share by Type in 2021
Figure 12. Global Anti-VEGF Medicine Revenue Market Share by Type (2017-2022)
Figure 13. Anti-VEGF Medicine Consumed in Hospital
Figure 14. Global Anti-VEGF Medicine Market: Hospital (2017-2022) & (K Units)
Figure 15. Anti-VEGF Medicine Consumed in Eye Clinic
Figure 16. Global Anti-VEGF Medicine Market: Eye Clinic (2017-2022) & (K Units)
Figure 17. Anti-VEGF Medicine Consumed in Other
Figure 18. Global Anti-VEGF Medicine Market: Other (2017-2022) & (K Units)
Figure 19. Global Anti-VEGF Medicine Sales Market Share by Application (2017-2022)
Figure 20. Global Anti-VEGF Medicine Revenue Market Share by Application in 2021
Figure 21. Anti-VEGF Medicine Revenue Market by Company in 2021 ($ Million)
Figure 22. Global Anti-VEGF Medicine Revenue Market Share by Company in 2021
Figure 23. Global Anti-VEGF Medicine Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global Anti-VEGF Medicine Revenue Market Share by Geographic Region in 2021
Figure 25. Global Anti-VEGF Medicine Sales Market Share by Region (2017-2022)
Figure 26. Global Anti-VEGF Medicine Revenue Market Share by Country/Region in 2021
Figure 27. Americas Anti-VEGF Medicine Sales 2017-2022 (K Units)
Figure 28. Americas Anti-VEGF Medicine Revenue 2017-2022 ($ Millions)
Figure 29. APAC Anti-VEGF Medicine Sales 2017-2022 (K Units)
Figure 30. APAC Anti-VEGF Medicine Revenue 2017-2022 ($ Millions)
Figure 31. Europe Anti-VEGF Medicine Sales 2017-2022 (K Units)
Figure 32. Europe Anti-VEGF Medicine Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa Anti-VEGF Medicine Sales 2017-2022 (K Units)
Figure 34. Middle East & Africa Anti-VEGF Medicine Revenue 2017-2022 ($ Millions)
Figure 35. Americas Anti-VEGF Medicine Sales Market Share by Country in 2021
Figure 36. Americas Anti-VEGF Medicine Revenue Market Share by Country in 2021
Figure 37. United States Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC Anti-VEGF Medicine Sales Market Share by Region in 2021
Figure 42. APAC Anti-VEGF Medicine Revenue Market Share by Regions in 2021
Figure 43. China Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 47. India Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe Anti-VEGF Medicine Sales Market Share by Country in 2021
Figure 50. Europe Anti-VEGF Medicine Revenue Market Share by Country in 2021
Figure 51. Germany Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 52. France Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa Anti-VEGF Medicine Sales Market Share by Country in 2021
Figure 57. Middle East & Africa Anti-VEGF Medicine Revenue Market Share by Country in 2021
Figure 58. Egypt Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country Anti-VEGF Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of Anti-VEGF Medicine in 2021
Figure 64. Manufacturing Process Analysis of Anti-VEGF Medicine
Figure 65. Industry Chain Structure of Anti-VEGF Medicine
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)